These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19884559)

  • 1. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.
    Gordon MS; Hussey M; Nagle RB; Lara PN; Mack PC; Dutcher J; Samlowski W; Clark JI; Quinn DI; Pan CX; Crawford D
    J Clin Oncol; 2009 Dec; 27(34):5788-93. PubMed ID: 19884559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    Hainsworth JD; Sosman JA; Spigel DR; Edwards DL; Baughman C; Greco A
    J Clin Oncol; 2005 Nov; 23(31):7889-96. PubMed ID: 16204015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
    Dawson NA; Guo C; Zak R; Dorsey B; Smoot J; Wong J; Hussain A
    Clin Cancer Res; 2004 Dec; 10(23):7812-9. PubMed ID: 15585612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
    El-Khoueiry AB; Rankin C; Siegel AB; Iqbal S; Gong IY; Micetich KC; Kayaleh OR; Lenz HJ; Blanke CD
    Br J Cancer; 2014 Feb; 110(4):882-7. PubMed ID: 24423918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Schöffski P; Wozniak A; Escudier B; Rutkowski P; Anthoney A; Bauer S; Sufliarsky J; van Herpen C; Lindner LH; Grünwald V; Zakotnik B; Lerut E; Debiec-Rychter M; Marréaud S; Lia M; Raveloarivahy T; Collette S; Albiges L
    Eur J Cancer; 2017 Dec; 87():147-163. PubMed ID: 29149761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
    Soulieres D; Senzer NN; Vokes EE; Hidalgo M; Agarwala SS; Siu LL
    J Clin Oncol; 2004 Jan; 22(1):77-85. PubMed ID: 14701768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
    Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
    Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.
    Gold KA; Kies MS; William WN; Johnson FM; Lee JJ; Glisson BS
    Cancer; 2018 May; 124(10):2169-2173. PubMed ID: 29579331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
    Lubner SJ; Mahoney MR; Kolesar JL; Loconte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD
    J Clin Oncol; 2010 Jul; 28(21):3491-7. PubMed ID: 20530271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.
    Shepard DR; Cooney MM; Elson P; Bukowski RM; Dreicer R; Rini BI; Garcia JA
    Invest New Drugs; 2012 Feb; 30(1):364-7. PubMed ID: 20711630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase 2 trial of erlotinib versus pemetrexed as second-line therapy in the treatment of patients with advanced EGFR wild-type and EGFR FISH-positive lung adenocarcinoma.
    Li N; Ou W; Yang H; Liu QW; Zhang SL; Wang BX; Wang SY
    Cancer; 2014 May; 120(9):1379-86. PubMed ID: 24481719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
    Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
    J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.
    Gordon AN; Finkler N; Edwards RP; Garcia AA; Crozier M; Irwin DH; Barrett E
    Int J Gynecol Cancer; 2005; 15(5):785-92. PubMed ID: 16174225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
    Hainsworth JD; Spigel DR; Sosman JA; Burris HA; Farley C; Cucullu H; Yost K; Hart LL; Sylvester L; Waterhouse DM; Greco FA
    Clin Genitourin Cancer; 2007 Dec; 5(7):427-32. PubMed ID: 18272024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.